The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Understanding the benefit of metformin use in cancer treatment
Open accessAbstract
Biguanides have been developed for the treatment of hyperglycemia and type 2 diabetes. Recently, metformin, the most widely prescribed biguanide, has emerged as a potential anticancer agent. Epidemiological, preclinical and clinical evidence supports the use of metformin as a cancer therapeutic. The ability of metformin to lower circulating insulin may be particularly important for the treatment of cancers known to be associated with hyperinsulinemia, such as those of the breast and colon. Moreover, metformin may exhibit direct inhibitory effects on cancer cells by inhibiting mammalian target of rapamycin (mTOR) signaling and protein synthesis. The evidence supporting a role for metformin in cancer therapy and its potential molecular mechanisms of action are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“At the cellular level, metformin activates AMP-activated protein kinase (AMPK), an energy sensor involved in regulating cellular metabolism that is activated by increases in the intracellular levels of AMP [14,15].”
BackgroundTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 3×
“Numerous observational studies reported decreased cancer incidence and cancer-related mortality in diabetics receiving standard doses of metformin (1500 to 2250 mg/day in adults) [11,24-28].”
BackgroundAMP-activated/SNF1 protein kinases: conserved guardians of cellular energy
Hardie, D. G. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2249 · Cited by 2,216
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
Towler, M. C., & Hardie, D. G. (2007) · Circulation Research · doi:10.1161/01.res.0000256090.42690.05 · Cited by 1,253
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 2×
“Some recent reports raise the possibility that metformin may mediate additional anticancer effects independently of AMPK, LKB1, and TSC2 [59,60].”
BackgroundThe AMP-activated protein kinase pathway – new players upstream and downstream
Hardie, D. G. (2004) · Journal of Cell Science · doi:10.1242/jcs.01540 · Cited by 1,143
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“The mechanism of metformin action in the treatment of diabetes involves the inhibition of hepatic gluconeogenesis and the stimulation of glucose uptake in muscle [20,21].”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Self-citationNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., & Hood, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.42 · Cited by 981
Self-citationBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Self-citationBuzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Self-citationMetformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“Furthermore, a recent epidemiological study of 2,529 women with breast cancer reported higher pathologic complete response rates (pCRs; considered a surrogate for overall survival in this setting) to neoadjuvant systemic therapy in diabetic patients receiving metformin (pCR 24%) compared to diabetic patients not recei…”
BackgroundSahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 2×
“In cell culture, metformin inhibits the proliferation of a range of cancer cells including breast, prostate, colon, endometrial, ovarian, and glioma [34-40].”
BackgroundAlimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 4×
“More recently, metformin has been associated with decreased cancer incidence and mortality in diabetic patients and the insulin-lowering effects of metformin may be integral to its anticancer properties [5,11-13].”
BackgroundInfluentialCusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Obesity and Cancer Risk: Recent Review and Evidence
Basen-Engquist, K., & Chang, M. (2011) · Current Oncology Reports · doi:10.1007/s11912-010-0139-7 · Cited by 439 · cited 1×
“Further, obesity and high insulin levels are adverse prognostic factors for a number of cancers particularly those of the breast, prostate and colon [25,50,52-54].”
BackgroundThe role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
The blooming of the French lilac
Witters, L. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14178 · Cited by 367
Metformin: its botanical background
Bailey, C., & Day, C. (2004) · Practical Diabetes International · doi:10.1002/pdi.606 · Cited by 353
Cantrell, L. A., Zhou, C., Mendivil, A., Malloy, K. M., Gehrig, P. A., & Bae-Jump, V. L. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.024 · Cited by 331
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
Gotlieb, W. H., Saumet, J., Beauchamp, M.-C., Gu, J., Lau, S., Pollak, M. N., & Bruchim, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.008 · Cited by 267
Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.060 · Cited by 228
Self-citationVazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13131 · Cited by 205
Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis
Isakovic, A., Harhaji, L., Stevanovic, D., Markovic, Z., Sumarac-Dumanovic, M., Starcevic, V., Micic, D., & Trajkovic, V. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7080-4 · Cited by 204
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor
Ish-Shalom, D., Christoffersen, C. T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko, R. M., Naor, D., & Meyts, P. D. (1997) · Diabetologia · doi:10.1007/s001250051393 · Cited by 193
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185 · cited 1×
“Metformin also reduced the growth of a variety of tumor xenografts in mice including those established from breast and prostate cancer cells [36,41], and suppressed the development of breast, colon and other tumors in transgenic mice [45,46].”
BackgroundAlgire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., & Pollak, M. (2011) · Oncogene · doi:10.1038/onc.2010.483 · Cited by 181
Vazquez-Martin, A., Oliveras-Ferraros, C., Barco, S. D., Martin-Castillo, B., & Menendez, J. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0924-x · Cited by 179
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 177
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 177
Self-citationStatus of PI3K inhibition and biomarker development in cancer therapeutics
Markman, B., Atzori, F., Pérez-García, J., Tabernero, J., & Baselga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 159
IGF and Insulin Receptor Signaling in Breast Cancer
Belfiore, A., & Frasca, F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9099-z · Cited by 151
Metformin in polycystic ovary syndrome
Diamanti‐Kandarakis, E., Economou, F., Palimeri, S., & Christakou, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05679.x · Cited by 109
Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
Mulligan, A. M., O’Malley, F. P., Ennis, M., Fantus, I. G., & Goodwin, P. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9471-x · Cited by 96
Self-citationClinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 90
Berstein, L. M. (2010) · Future Oncology · doi:10.2217/fon.10.87 · Cited by 54
Hadden, D. R. (2005) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520053503010 · Cited by 46
Metformin Beyond Diabetes: New Life for an Old Drug
Rotella, C. M., Monami, M., & Mannucci, E. (2006) · Current Diabetes Reviews · doi:10.2174/157339906777950651 · Cited by 41
Hadden, D. R. (2005) · PubMed · Cited by 38
Metabolic Immunodepression and Metabolic Immunotherapy
Dilman, V. M., Berstein, L. M., Ostroumova, M. N., Fedorov, S. N., Poroshina, T. E., Tsyrlina, E. V., Buslaeva, V. P., Семиглазов, В. Ф., Ik, S., Bobrov, Y. F., et al. (2009) · Oncology · doi:10.1159/000225596 · Cited by 34
Preliminary evidence on metabolic rehabilitation of cancer patients.
Vm, D., Berstein, L. M., Tp, E., YeV, T., Mn, O., YuF, B., SYu, R., Kovalenko, I. G., & Nn, S. (1988) · PubMed · Cited by 33
Cited by
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967
“However, the real and potential benefits of metformin therapy go beyond its prescribed usage, including reduced risk of cancer (Dowling et al., 2011) and, in animal models, delayed aging, an effect seen in rodents (Anisimov et al.”
BackgroundRapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
“Interestingly, a long-term study in human patients found that treatment with metformin in patients with diabetes decreased mortality from all causes, including diabetesrelated mortality, cancer, and myocardial infarction (108, 109).”
BackgroundMetformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
mTOR as a central regulator of lifespan and aging
Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F., Topisirovic, I., & Hulea, L. (2019) · F1000Research · doi:10.12688/f1000research.17196.1 · Cited by 440
How ageing processes influence cancer
de Magalhães, J. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3497 · Cited by 367
Metadata
- Authors
- Dowling, R. J., Goodwin, P. J., & Stambolic, V.
- Venue
- BMC Medicine
- Published
- 2011-04-06
- Volume
- 9
- Issue
- 1
- Pages
- 33-33
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2042008937
- Cited by
- 409
- References
- 61
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.